{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:03:13Z","timestamp":1761843793785,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.bcmd.2008.06.008","type":"journal-article","created":{"date-parts":[[2008,8,20]],"date-time":"2008-08-20T15:14:11Z","timestamp":1219245251000},"page":"284-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders"],"prefix":"10.1016","volume":"41","author":[{"given":"Selcuk","family":"Sozer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Isabel","family":"Fiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takefumi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiapeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Wisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2008.06.008_bib1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2008.06.008_bib2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcmd.2008.06.008_bib3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2008.06.008_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.bcmd.2008.06.008_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.bcmd.2008.06.008_bib6","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2008.06.008_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.06.008_bib8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF01707281","article-title":"Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients","volume":"63","author":"Wehmeier","year":"1991","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2008.06.008_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminhematol.2004.02.008","article-title":"Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders","volume":"41","author":"Craig","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2008.06.008_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2005.05.023","article-title":"Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils","author":"Falanga","year":"2005","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2008.06.008_bib11","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera","author":"Falanga","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.06.008_bib12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/09537100412331272541","article-title":"Abnormal vascular, platelet and coagulation markers in primary thrombocythaemia are not reversed by treatments that reduce the platelet count","volume":"1","author":"Blann","year":"2004","journal-title":"Platelets"},{"key":"10.1016\/j.bcmd.2008.06.008_bib13","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2008.06.008_bib14","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1053\/j.gastro.2006.04.008","article-title":"Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd\u2013Chiari syndrome","volume":"130","author":"Patel","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcmd.2008.06.008_bib15","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1538-7836.2007.02626.x","article-title":"Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies","volume":"5","author":"Robertson","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2008.06.008_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/s-2006-942759","article-title":"The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia","volume":"32","author":"Bellucci","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.bcmd.2008.06.008_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.molmed.2004.02.001","article-title":"Role of eNOS in neovascularization: NO for endothelial progenitor cells","volume":"10","author":"Duda","year":"2004","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bcmd.2008.06.008_bib18","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0301-472X(03)00255-8","article-title":"Converging roads: evidence for an adult hemangioblast","volume":"31","author":"Bailey","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bcmd.2008.06.008_bib19","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1600-0463.2005.apm_317.x","article-title":"The embryonic origins of hematopoietic stem cells: a tale of hemangioblast and hemogenic endothelium","volume":"113","author":"Bollerot","year":"2005","journal-title":"APMIS"},{"key":"10.1016\/j.bcmd.2008.06.008_bib20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.exphem.2005.06.005","article-title":"From hemangioblast to hematopoietic stem cell: an endothelial connection?","volume":"33","author":"Jaffredo","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bcmd.2008.06.008_bib21","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.exphem.2005.06.003","article-title":"Evidence for the hemangioblast","volume":"33","author":"Park","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bcmd.2008.06.008_bib22","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/blood-2002-05-1511","article-title":"Identification of the hemangioblast in postnatal life","volume":"100","author":"Pelosi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.06.008_bib23","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.exphem.2007.01.047","article-title":"Are postnatal hemangioblasts generated by dedifferentiation from committed hematopoietic stem cells?","volume":"35","author":"Prindull","year":"2007","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.bcmd.2008.06.008_bib24","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood-2006-06-031898","article-title":"The megakaryocyte lineage originates from hemangioblast precursors and is an integral component both of primitive and of definitive hematopoiesis","volume":"109","author":"Tober","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.06.008_bib25","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bcmd.2008.06.008_bib26","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2006-08-043471","article-title":"Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem\/progenitor cell principals","volume":"109","author":"Yoder","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.06.008_bib27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/sj.leu.2404676","article-title":"Working hypothesis to redefine endothelial progenitor cells","volume":"21","author":"Prater","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2008.06.008_bib28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMoa022287","article-title":"Circulating endothelial progenitor cells, vascular function, and cardiovascular risk","volume":"348","author":"Hill","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2008.06.008_bib29","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2008.06.008_bib30","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/0008-5472.CAN-07-0572","article-title":"Effects of chromatin-modifying agents on cd34+ cells from patients with idiopathic myelofibrosis","volume":"67","author":"Shi","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcmd.2008.06.008_bib31","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/CIRCULATIONAHA.104.504340","article-title":"Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair","volume":"111","author":"Schmidt-Lucke","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.bcmd.2008.06.008_bib32","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa043814","article-title":"Circulating endothelial progenitor cells and cardiovascular outcomes","volume":"353","author":"Werner","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2008.06.008_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJMp020175","article-title":"Endothelial progenitor cells","volume":"348","author":"Rosenzweig","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2008.06.008_bib34","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1056\/NEJMe058134","article-title":"Circulating endothelial progenitors\u2014cells as biomarkers","volume":"353","author":"Rosenzweig","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2008.06.008_bib35","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/86498","article-title":"Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function","volume":"7","author":"Kocher","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcmd.2008.06.008_bib36","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1200\/JCO.2005.09.021","article-title":"Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia","volume":"23","author":"Massa","year":"2005","journal-title":"J. Clin. Oncol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979608001423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979608001423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:25:04Z","timestamp":1761049504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979608001423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S1079979608001423"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2008.06.008","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating angiogenic monocyte progenitor cells are reduced in JAK2V617F high allele burden myeloproliferative disorders","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2008.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}